Stephen Chen is a patent agent in the Patents group. He focuses his practice on intellectual property protection and counseling for life sciences technology clients.
What do you focus on?
I leverage my science background in molecular biology and biochemistry to advise clients in obtaining protection for their intellectual property assets. I work with research universities, hospitals and biotechnology companies seeking to develop and maintain an intellectual property strategy. This further includes obtaining patents on behalf of clients, providing guidance on their intellectual property portfolios and those of their competitors.
Regenerative Medicine | Stem Cells
I have research experience with stem cells and specific experience in the patenting of regenerative medicine technologies in the U.S. and foreign countries. I regularly interact with leading stem cell experts to learn of the latest developments in this technology field and consult regularly with foreign lawyers on ethical issues related to stem cell patenting.
Nanotechnology | Molecular Detection
I also focus on micro- and nano-sized devices that are used for molecular detection. These technologies rely on not only biological, but chemical and electrical innovations for medical and biotechnology research applications.
What do you see on the horizon?
I believe that the breakthroughs and benefits of regenerative medicine will deliver dramatic improvements to personal health and become critically important for an aging society.
- “‘What, How, and Why’ Social Morality Provisions Play a Role in Determining Human Embryonic Stem Cell Patent Eligibility in Different Countries,” World Stem Cell Summit, Pasadena, CA 2011. (Presentation)
- “Patent Protection in Medicine and Biotechnology: An Overview,” Journal of Health and Life Sciences Law. 4 (2011): 106–158.
- “Comparison of National Innovation Systems (NIS) in China, Taiwan and Singapore: Is Bayh-Dole One-Size That Fits All?” Tomorrow’s Technology Today. 2 (2010): 26–37.
- “Comparison of National Innovation Systems (NIS) in China, Taiwan and Singapore: Is Bayh-Dole One-Size That Fits All?” (Amore G, ed.), AUTM Technology Transfer Practice Manual, 3rd edition, Deerfield, IL: Association of University Technology Managers.
- “Fluorescently Labeled Short Oligos: A Simple, Economic Method for Establishing Efficient siRNAKnockdown in Mouse Embryonic Stem Cells,” B. Zhang, ed., RNAi and microRNA-Mediated Gene Regulation in Stem Cells, Totowa, NJ: Humana Press (2009). (First author)
- “Knockdown of Oct4 and Sox2 Attenuate Neurogenesis of Mouse Embryonic Stem Cells,” Stem Cells and Development, 16 (2007): 413–420. (First author)
- “Establishing Efficient siRNA Knockdown in Mouse Embryonic Stem Cells,” Biotechnology Letters, 29 (2007): 261–5. (First author)
- “TGF-β2 Allows Pluripotent Human Embryonic Stem Cell Proliferation on E6/E7 Immortalized Mouse Embryonic Fibroblasts,” Journal of Biotechnology, 122 (2006): 341–61. 2006. (First author)
- “Involvement of Oct-3/4 and Sox-2 in RNAi Mediated SDIA (Stromal Derived Inducing Activity) Neurogenesis from Mouse Embryonic Stem Cells,” International Society for Stem Cell Research, Toronto, CA, 2006. (Presentation)
- “Assessment of Stem Cell Markers During Long Term Cultures of Embryonic Stem Cells,” Cytotechnology, 44 (2004): 77–91. (Contributor)
- “Role of Inflammation in Alzheimer’s Disease,” Caltech Summer Undergraduate Research Fellowship (SURF) Seminar Day, Pasadena, CA, 1999. (Presentation)